Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient
- 15 January 2013
- journal article
- case report
- Published by Taylor & Francis Ltd in Platelets
- Vol. 25 (1), 69-70
- https://doi.org/10.3109/09537104.2012.758360
Abstract
Glucocorticosteroids, intravenous immunoglobulins, vincristine, danazol, and eltrombopag are used in refractory chronic idiopathic thrombocytopenic purpura (ITP). All those treatment modalities are susceptible for thrombosis generation. There is an increased risk of thrombosis in the diseases’ natural course. The case we present is a resistant chronic ITP patient who developed pulmonary and intracardiac thrombosis during multidrug treatment. Risk of concomitant usage of drugs and rapid increase in platelet count are discussed.Keywords
This publication has 7 references indexed in Scilit:
- Thrombosis in patients with primary chronic immune thrombocytopeniaThrombosis Research, 2012
- Eltrombopag before Procedures in Patients with Cirrhosis and ThrombocytopeniaThe New England Journal of Medicine, 2012
- Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic PurpuraThe New England Journal of Medicine, 2007
- Management of Immune Thrombocytopenic Purpura in AdultsMayo Clinic Proceedings, 2004
- Immune Thrombocytopenic PurpuraThe New England Journal of Medicine, 2002
- Effect of Danazol in Immune Thrombocytopenic PurpuraThe New England Journal of Medicine, 1987